Aksamon - a cholinesterase inhibitor, an agent for the treatment of disorders of the nervous system.

Release form and composition

Aksamon produced tablets and solution for subcutaneous or intramuscular administration.

The active ingredient in all forms of the drug is ipidakrina hydrochloride monohydrate. 1 tablet contains 15 mg of active substance. Excipients in tablets are the sodium carboxymethyl starch, and calcium stearate ludipress. The solution - 0 1 M hydrochloric acid solution and water for injection.


According to the instructions, Aksamon prescribed for the treatment of:

  • Polyneuritis;
  • Neuritis;
  • Myasthenia gravis and myasthenic syndromes;
  • Multiple Sclerosis;
  • Mielopoliradikulonevrita;
  • Neuropathy;
  • Paresis, bulbar paralysis, accompanied by movement disorders;
  • Alzheimer's disease;
  • Encephalopathy vascular, traumatic and other origins;
  • Circulatory disorders of the brain.

According to the instructions, Aksamon effectively eliminates functional disorders of the nervous system, such as disorientation, lability, poor concentration, memory impairment. The product includes a comprehensive treatment of demyelinating diseases, prescribed for traumatic brain injuries.

A lot of positive feedback on the application of Aksamona for the treatment of children with cerebral dysfunction and learning difficulties. It is also noted that due to the relaxing effect on the muscles of the drug can be used in uterine inertia, and intestinal atony.


According to the instructions, can not be used when Aksamon:

  • Epilepsy;
  • Angina;
  • Bradycardia;
  • Bronchial asthma;
  • Extrapyramidal and vestibular disorders;
  • Sensitivity to the drug;
  • Lactation;
  • Pregnancy.

The drug is contraindicated in children under 18 years.

Dosage and Administration

Aksamon administered intramuscularly, subcutaneously and is taken orally.

In the peripheral nervous system lesions administered 20 mg three times a day.

At myasthenia gravis, myasthenic syndrome, demyelinating lesions of the nervous system using a higher dosage of 20-40 mg 4-5 times a day. The maximum permitted daily dose - 180-200 mg.

For the treatment of Alzheimer's disease and other forms of dementia dosage is adjusted individually, at an average of 10-20 mg 2-3 times a day. It is recognized that the administered per day may be not more than 200 mg. Duration of treatment - from 1 to 12 months.

In appointing the drug in high doses it is recommended to take it 4-5 times a day with an interval of 2-3 hours.

When intestinal atony appoint 15-20 mg 2-3 times a day for 1-2 weeks.

side effects

Formulation tolerated in most cases well. In some cases, the use of Aksamona causes:

  • Nausea;
  • Jaundice;
  • Diarrhea;
  • Vomiting;
  • Appetite loss;
  • Increased intestinal motility;
  • Dizziness;
  • Ataxia;
  • Rash;
  • Itching;
  • Chest pain;
  • Bradycardia;
  • Bronchospasm;
  • Lowering the body temperature;
  • Increased sweating;
  • Weakness;
  • Drowsiness;
  • Tremor of limbs;
  • Cramps;
  • Headache;
  • Convulsions.


During the period of Aksamona undesirable to drink alcohol, engage in activities requiring increased attention and speed of reaction. Also, when you use is advised to avoid driving a car.

Patients with ulcerative lesions of the gastrointestinal tract, thyrotoxicosis, diseases of the cardiovascular system should take the drug only under medical supervision.

Means prescription.


Among peers Aksamona drugs can be identified: Ipidakrin, Amiridin and Neiromidin.

Terms and conditions of storage

The drug should be stored in a dark, dry place, away from children, at temperatures up to 25 ° C.

Shelf life is 2 years Aksamona.